A phase I trial of camrelizumab in combination with apatinib (vascular endothelial growth factor receptor 2 [VEGFR2] inhibitor) in the treatment of HCC, gastric cancer, and gastroesophageal junction cancer (NCT02942329) (27) was performed. This evidence concerns the gene KDR and hepatocellular carcinoma.